Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
NAD+ at a glance
- What it is
- Nicotinamide adenine dinucleotide, an endogenous coenzyme central to cellular energy metabolism, supplied as a lyophilized powder for subcutaneous or IV research use.
- Researched for
- Cellular energy metabolism, mitochondrial function, DNA repair and sirtuin activity in preclinical and early clinical contexts.
- Commonly reported range
- 50-100 mg subcutaneous per injection (community-reported); higher amounts reported for IV in clinical settings.
- Route reported
- Subcutaneous injection most common in community protocols; intravenous infusion in clinical settings.
- Reported frequency
- 2-3 times per week (subcutaneous), often after a low-dose tolerance start.
- Reported cycle
- Commonly described as 4-12 week courses, sometimes bridged with oral precursors (NMN/NR).
- Plasma half-life
- Short; serum half-life reported under ~1 hour, with rapid intracellular uptake.
- Regulatory status
- Not FDA-approved; available only via compounding pharmacies for research/clinical use. Not listed as prohibited by WADA (2026).
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell that acts as an electron carrier in the mitochondrial electron transport chain, where it is central to ATP (energy) production. Beyond bioenergetics, NAD+ is a required substrate for two important enzyme families: sirtuins (SIRT1-7), which are involved in DNA repair, metabolic regulation and gene expression, and PARP enzymes, which participate in DNA damage response. Cellular NAD+ levels are reported to decline with age, which has driven research interest in NAD+ and its precursors (NMN, NR) as tools for studying cellular aging and metabolism. Injectable NAD+ is proposed to bypass hepatic first-pass metabolism, with subcutaneous administration creating a depot that is absorbed gradually. The precise pharmacokinetics of injected NAD+ in humans remain incompletely characterized in the published literature.
Researched effects
In preclinical and early clinical research, restoring NAD+ availability has been associated with markers of improved mitochondrial function, cellular energy metabolism and DNA repair activity. Community-reported observations from injectable protocols include subjective changes in energy and physical performance, and one small randomized trial in adults over 45 reported improvements in self-reported energy and performance scores versus placebo. These are research findings and community reports, not guaranteed outcomes; controlled human trial data for injectable NAD+ remains limited, and individual responses vary.
Evidence & regulatory status
- Evidence: NAD+ biology is well characterized in cell and animal models, but controlled human trials of injectable NAD+ are small and limited; most efficacy claims remain preliminary and unproven at scale.
- Regulatory: Injectable NAD+ is not FDA-approved for any therapeutic indication and is available only through compounding pharmacies (503A/503B) under prescription. It is not listed as prohibited by WADA as of 2026.
- Research use: Information here is for educational and research-planning purposes only. NAD+ described in this context is a research chemical, not an approved drug or supplement, and is not intended to diagnose, treat, cure or prevent any disease.
Dosage — reported ranges (overview)
The figures below are examples of what is reported in community and clinical-planning contexts, not a recommendation or a personal dose. Subcutaneous protocols most commonly report 50-100 mg per injection, 2-3 times per week, frequently beginning with a lower dose (for example 50 mg) as a tolerance start before titrating upward. Because subcutaneous NAD+ is often associated with injection-site burning, some protocols split doses or use buffered formulations. Intravenous NAD+ in clinical settings uses substantially higher amounts (hundreds of mg to over 1,000 mg) infused slowly. None of these figures constitute medical advice.
A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.
Reconstitution — bac-water math
NAD+ is dosed in milligrams, so reconstitution is concentration math. After adding bacteriostatic water to the lyophilized vial, concentration (mg/mL) = total mg in the vial ÷ mL of water added. On a U-100 insulin syringe, 100 units = 1 mL, so the volume for a given dose is (dose in mg ÷ concentration in mg/mL), and units drawn = that volume in mL × 100. Worked example: a 500 mg vial reconstituted with 2 mL of bacteriostatic water gives 250 mg/mL. A 50 mg example dose is then 50 ÷ 250 = 0.2 mL, or 20 units on a U-100 syringe. This is concentration math only, not a personal dose recommendation.
| Bac water added | Concentration | 50 mg dose | 100 mg dose |
|---|
| 1 mL | 500 mg/mL | 10 units (0.1 mL) | 20 units (0.2 mL) |
| 2 mL | 250 mg/mL | 20 units (0.2 mL) | 40 units (0.4 mL) |
| 3 mL | 167 mg/mL | 30 units (0.3 mL) | 60 units (0.6 mL) |
This is concentration math, not a dose recommendation.
Injection / administration basics
In community protocols, reconstituted NAD+ is typically drawn into a U-100 insulin syringe and administered subcutaneously into fatty tissue such as the abdomen, with the vial stored refrigerated after mixing. Subcutaneous NAD+ is frequently reported to cause a burning or stinging sensation during injection; slower injection, smaller split doses and buffered formulations are commonly described as ways to reduce this. These are general handling notes for research context, not medical or administration advice; only a licensed professional can advise on injections.
Half-life & frequency rationale
Injectable NAD+ has a short serum presence, with reported half-life generally under about one hour and rapid intracellular incorporation (IV estimates around 45 minutes). Subcutaneous administration is thought to produce lower peak concentrations but more gradual, sustained tissue exposure via a depot effect. Overall, injectable NAD+ pharmacokinetics in humans are described in the literature as incompletely characterized.
Side effects, safety & contraindications
Community- and clinic-reported side effects are usually mild and short-lived: injection-site discomfort or burning (notably with unbuffered subcutaneous formulations), transient flushing or warmth, brief nausea, and mild headache. With IV administration, nausea, chest tightness and facial flushing are reported when infused too rapidly, and side effects such as nausea, flushing and cramping are reported to become more common at higher amounts (e.g. above ~250 mg). Human safety data for injectable NAD+ is limited, and any use should involve a licensed healthcare professional.
Stacking — overview
NAD+ is commonly discussed in longevity and cellular-energy research contexts alongside other mitochondrial- and repair-focused compounds. The pairings below are examples reported in community protocols, not recommendations, and combining research compounds increases uncertainty around effects and tolerability.
Mitochondrial energy pairing
NAD+ + MOTS-c
Cellular-repair longevity stack
NAD+ + Epithalon
Mitochondrial protection stack
NAD+ + SS-31
Systemic recovery pairing
NAD+ + BPC-157
Stacking across compounds
The overview above covers NAD+. The cross-compound material — which pairings are redundant rather than additive, where interaction risk is documented versus merely unstudied, and the blend arithmetic worked end to end — lives in the Peptide Stacking Guide, which is free to read in outline and $39 in full (included with All-Access Lifetime).
Included with this guide
The NAD+ Stacking Module
The overview above is the free summary. The NAD+ Stacking Module goes through each combination in depth — the mechanism-level reason it is proposed, what is actually reported in practice, and the cautions specific to that pairing — plus what to avoid and why. Included with NAD+ Standard Access.
- How to think about stacking NAD+ — 4 principles
- 4 combinations covered in detail
- What to avoid, and why — 3 items
- Combination-specific cautions
Combinations covered: Mitochondrial energy pairing, Mitochondrial protection stack, Cellular-repair longevity stack, Systemic recovery pairing.
For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.
Storage & handling
- Lyophilized (powder) vials are reported to be stable stored refrigerated (2-8°C) and protected from light; many sources note the powder can tolerate short periods at room temperature during shipping.
- Once reconstituted with bacteriostatic water, NAD+ should be kept refrigerated (2-8°C), protected from light, and used within a few weeks per common handling guidance.
References
Information synthesized from published NAD+ biology literature, early clinical trial reports, compounding-pharmacy and community protocol resources, and the 2026 WADA Prohibited List; provided for educational purposes only and not as medical advice.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Guide FAQ
Quick answers about guide scope, access, and educational use context.
Is injectable NAD+ FDA-approved?
No. Injectable NAD+ is not FDA-approved for any therapeutic indication. It is available only through compounding pharmacies under prescription for clinical use, and is handled as a research chemical in educational contexts. Nothing here is medical advice.
What subcutaneous dose is commonly reported?
Community protocols most often report 50-100 mg per subcutaneous injection, 2-3 times per week, frequently starting lower (around 50 mg) as a tolerance test. These are reported examples, not a personal dose recommendation.
Why does subcutaneous NAD+ sometimes burn or sting?
Subcutaneous NAD+ is frequently reported to cause a burning or stinging sensation, especially with unbuffered formulations. Slower injection, smaller split doses and buffered preparations are commonly described as ways to reduce this discomfort.
How is NAD+ different from NMN or NR?
NMN and NR are NAD+ precursors that cells convert into NAD+, and are typically taken orally. Injectable NAD+ delivers the coenzyme itself. Some protocols use oral precursors as a bridge between injectable courses. This is descriptive information, not a recommendation.
Is NAD+ prohibited in sport?
As of the 2026 WADA Prohibited List, NAD+ is not listed as a prohibited substance. Athletes should always verify current status with their governing body, as lists are updated periodically.
Compliance and trust notes
- Educational content only; no personalized health or outcome claims.
- No personalized use recommendation outputs.
- Use this material for general learning and research-context literacy.
